RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma
Authors: Ze Zhang
Baoxing Jia
Peiqiang Jiang
Qingmin Chen
Yahui Liu
Journal: Human Cell (2020)
Discipline: MOLECULAR BIOLOGY & GENETICS
Keywords: AKT pathway; Chemoresistance; Hepatocellular carcinoma; Metastasis; RCC2.
Affiliations: Department of General Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin, China., Department of General Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin, China. ., Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130000, Jilin, China. .

Abstract:  Tumor metastasis and chemoresistance are the main causes of treatment failure and high mortality in hepatocellular carcinoma (HCC). Therefore, it is critical to clarify the biological action and potential mechanisms in HCC cells to develop novel therapeutics. The regulator of chromosome condensation 2 (RCC2), a component of the chromosomal passenger complex, was shown to have important roles in tumor development and radio-chemotherapy resistance. However, its role in the aggressive phenotypes and cisplatin (DDP)-resistance of HCC is not known. Therefore, this study aimed to investigate the role of RCC2 in HCC pathogenesis. Interestingly, we found that RCC2 was upregulated in HCC patient specimens and HCC cell lines and was correlated with the pathological grade of HCC. To evaluate the function of RCC2 in HCC cell, lentivirus vector-based shRNAs were transfected into HCC cells. Silencing RCC2 inhibited the HCC cell proliferation, migration, invasion, and increased the apoptosis rate upon DDP treatment. Further analysis showed that RCC2-mediated downregulation of the expression of survival proteins occurred via the AKT and Bcl2 pathways. Our results suggest that RCC2 might act as an oncogenic protein promoting metastatic behaviors and cisplatin resistance in HCC cells, and thereby could be a potential prognostic biomarker and therapeutic target for HCC. 

Retracted: No

PubPeer comments:
 Figure 3C. * Red boxes: Two panels appear to show an overlap, with a rotation. ![file] , 
 Figure 1B: the Western blots here look very similar to those in Figure 1B of another paper by the same group. They might be representing the same patient samples, but the top panel is representing a different protein. * Left: Qingmin Chen et al., BioMed Research International (2020), DOI: 10.1155 2020 3098327 * Right: Qingmin Chen et al., Human Cell (2020), DOI: 10.1007 s13577-020-00353-7 ![file] , 
 Dear Bik: Thank you for pointing out the misuse of pictures in our manuscript. We are very sorry about that. WB band in the u201cFigure 1bu201d listed above were erroneously presented, so we will make a corrigendum. The corrected figure is presented below. We all authors confirm that this correction does not change our results and conclusion. As for the u201cFigure 3Cu201d, it is due to our negligent picture selection. We deeply grateful for your pointing out our mistakes. We will contact the magazine for correction as soon as possible. ![file] , 
 Correction, February 2021: https: link.springer.com article 10.1007 s13577-020-00480-1  In the original publication of the article, Fig. 1 and Fig. 3 were published with errors. The correct Fig. 1 and 3 are given in this correction. ,